We could not find any results for:
Make sure your spelling is correct or try broadening your search.
RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5% Consolidated net revenue of € 1,743.1 million in the...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi...
L’étude LINC 4 a démontré la supériorité d’Isturisa® (osilodrostat) comparé au placebo pour normaliser le cortisol au cours de la phase de 12 semaines en double aveugle, randomisée de l’étude (77...
RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER...
Statistically significant results from the pivotal Phase III LINC 4 study demonstrate that Isturisa® (osilodrostat) provides rapid and sustained normalisation of mean urinary free cortisol levels...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.6 | 3.09178743961 | 51.75 | 54.2 | 51.15 | 214898 | 52.6282681 | DE |
4 | 2.2 | 4.30107526882 | 51.15 | 54.2 | 49.16 | 239250 | 51.20783909 | DE |
12 | -1.2 | -2.19981668194 | 54.55 | 54.65 | 48.58 | 258159 | 51.65101826 | DE |
26 | 4.35 | 8.87755102041 | 49 | 54.8 | 47.98 | 248831 | 51.39005453 | DE |
52 | 4.47 | 9.14484451718 | 48.88 | 54.8 | 47.28 | 238410 | 50.83316528 | DE |
156 | -0.95 | -1.74953959484 | 54.3 | 55.08 | 34.52 | 235474 | 45.60188842 | DE |
260 | 14.55 | 37.5 | 38.8 | 57.9 | 28.26 | 279778 | 45.09472476 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions